viewZynerba Pharmaceuticals

Zynerba Pharmaceuticals adds pharma exec to its board

Pamela Stephenson brings expertise in commercial planning to the developer of transdermal cannabinoid therapies

board room table
The Devon, Pennsylvania company develops transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said Wednesday that it has appointed Pamela Stephenson to its board of directors.

Stephenson is currently vice president of Global Market Access and Value at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), where she has served since 2008. Prior to that, she spent 10 years at Pfizer Inc (NYSE:PFE) in various capacities.

“Zynerba is in an important phase of its journey as it begins its preparations for a potential launch of the first product ever indicated for use in children and adolescents with Fragile X Syndrome,” said Stephenson in a statement. “I am excited to join Zynerba’s board of directors at this time, and look forward to contributing to the company’s future successes.”

The Devon, Pennsylvania, company develops transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X Syndrome – a genetic cause of intellectual disability -- and Autism Spectrum Disorder.

“Pamela brings with her a wealth of expertise in commercial planning, market development, product launch and market access,” said Zynerba CEO Armando Anido. “This experience will be essential as we develop the market for ZYN002 in Fragile X Syndrome and await data from our ongoing pivotal CONNECT-FX study.”

Zynerba shares closed at $5.03 Tuesday.

Contact Paul Curcio at paul.curcio@proactiveinvestors.com

Follow him on Twitter @GoCurcioGo

Quick facts: Zynerba Pharmaceuticals

Price: 3.27 USD

Market: NASDAQ
Market Cap: $95.66 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...


Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021. Zynerba is on track to report top-line results from tests...

on 03/12/2019

2 min read